Hope for the Orphans
At a conference I attended last month in Washington DC, I learned that investors, pharmaceutical companies and researchers see rare disease treatments as a potential “next frontier” in the world of drug and device development. We’re living in a time when the blockbuster meds designed for more common ailments may be becoming less profitable while … Read more